286 related articles for article (PubMed ID: 15195702)
1. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
Rudzki Z; Papla B; Stachura J
Pol J Pathol; 2004; 55(1):13-23. PubMed ID: 15195702
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
3. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.
Florena AM; Tripodo C; Iannitto E; Porcasi R; Ingrao S; Franco V
Haematologica; 2004 Aug; 89(8):911-9. PubMed ID: 15339673
[TBL] [Abstract][Full Text] [Related]
4. Single chromosomal abnormalities in Philadelphia-negative chronic myeloproliferative disorders.
Panani AD
In Vivo; 2007; 21(5):867-70. PubMed ID: 18019426
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
Thiele J; Kvasnicka HM
Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
[TBL] [Abstract][Full Text] [Related]
6. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
7. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders.
Bock O; Tessema M; Serinsöz E; von Wasielewski R; Büsche G; Kreipe H
Leuk Res; 2004 Nov; 28(11):1145-51. PubMed ID: 15380337
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach.
Thiele J; Kvasnicka HM; Orazi A
Semin Hematol; 2005 Oct; 42(4):184-95. PubMed ID: 16210032
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
11. [Jamshidi biopsy in clinical hematology. Method, indications and results of over 1,000 completed biopsies with special reference to chronic myeloproliferative diseases].
Seewann HL
Wien Med Wochenschr Suppl; 1986; 100():1-24. PubMed ID: 3471009
[TBL] [Abstract][Full Text] [Related]
12. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
Thiele J; Kvasnicka HM; Zankovich R; Diehl V
Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
14. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
Kreipe HH
Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
[TBL] [Abstract][Full Text] [Related]
15. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
[TBL] [Abstract][Full Text] [Related]
16. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
[TBL] [Abstract][Full Text] [Related]
17. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.
Panteli K; Zagorianakou N; Bai M; Katsaraki A; Agnantis NJ; Bourantas K
Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
[TBL] [Abstract][Full Text] [Related]
20. Modern diagnostics in chronic myeloproliferative diseases (CMPDs).
Haferlach T; Kern W; Schnittger S; Schoch C
Ann Hematol; 2004; 83 Suppl 1():S59-61. PubMed ID: 15124674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]